Beyondspring, Inc.NASDAQ: BYSI

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition

· Issued by Beyondspring, Inc.
  • Adding plinabulin to a myelosuppressive chemotherapy regimen rapidly reversed (within 24 hours) chemotherapy-induced neutropenia and leukopenia in the PROTECTIVE-1 and -2 clinical studies, suggesting protection of the granulocyte-monocyte-progenitor stem cells as plinabulin’s mechanism of action for the prevention of chemotherapy-induced neutropenia (CIN), at a level of p0.5x10E9/L without plinabulin)
  • Monocytes (p=0.0023)
  • Eosinophils (p=0.0775)
  • Basophils (p

Company analysis